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Objectives: Smoking in diabetics is associated with a worse prognosis and vascular 
complications. The available evidence on health care resources utilization and associ-
ated costs in diabetics who smoke is limited or nonexistent. Thus, the objective was 
to compare health care resource utilization and costs according to smoking status in 
patients with type 2 diabetes in clinical practice. MethOds: A retrospective cohort 
nested case-control study was designed. Cases were current smokers, while two types 
of controls (former smokers and never smokers) were matched, two controls per 
case, for age, sex, duration of diabetes, and burden of comorbidity using data from 
electronic medical records. Non-institutionalized diabetics, both genders, age > 18 
years, seen consecutively over a 5-year period before the index date were enrolled. 
Perspective of both the National Health System and the Society were chosen and costs 
of health care resource utilization and loss of productivity due to sick leaves were 
compared among groups using a linear general model with covariates. Results: A 
total of 2,490 records were analyzed: 498 from cases, 996 from former smokers, and 
996 from never smokers. Mean age was 63.4 years (64.9% male). Smokers had higher 
HbA1c (7.4% vs. 7.2% and 7.2%, respectively, p = 0.013) and a lower degree of metabolic 
control (49.2 % vs. 54.7% and 55.8%, p = 0.036). Smokers had higher average annual 
costs (€ 3,583) than former smokers (€ 2,885) and never smokers (€ 2,183), p< 0.001. Mean 
annual health care cost saving per patient was associated with elapsed time of quit-
ting smoking from € 950 in subjects quitting smoking 2-year to € 1173 5-year or more, 
p< 0.05. cOnclusiOns: Diabetic smoker patients had lower metabolic control, higher 
health resource utilization, and more sick leave, resulting in higher health care costs 
and lost productivity compared with both former and never diabetic smokers. Health 
care cost-savings was associated with elapsed time from quitting smoking.
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Objectives: The aim of this analysis was to estimate the potential GH waste per 
patient with pen devices and the easypod® device, and to quantify the potential 
economic impact of expected GH waste from patient and health care organization 
perspectives. MethOds: A Waste Calculator Model was developed to examine GH 
waste. All somatropin products available in pen or electronic devices were included. 
The user may define distribution across cartridges sizes. The mechanical/priming 
loss applied to each product was based upon each product’s prescribing information 
and/or instructions for use. The base case model utilizes a US patient daily dose of 1.4 
mg. The model assumes that the easypod® dose adjustment feature is activated by 
the clinician (±25%). Model assumes that 42.6% of caregivers discard the remaining 
amount left in the cartridge (eg waste) if less than a full dose. Annual amount of GH 
waste (mg, cartridges, dollars) per patient and per population (based on US national 
market shares) for each pen/device is reported. Results: The expected annual 
amount of waste per patient was lowest for easypod®. The expected annual amount 
of waste per patient was highest for Omnitrope®. The expected annual amount of 
waste ranged from 0 to 38.9mg per patient per year, which is equal to 0 to 8 cartridges 
per patient per year and/or 0 to $2,935 per patient per year. For a patient population 
of 100 GH-treated patients, the annual amount of waste is estimated at 2,009 mg, 
which can be translated into approximately 342 cartridges or about $162,000 per year. 
The results in GH waste fluctuated depending upon daily dose, cartridge size, and 
dose spread assumptions. cOnclusiOns: The expected annual amount of GH waste 
evaluated in this Waste Calculator was lowest with easypod®. Cost of GH waste can 
be an important consideration when evaluating GH delivery devices.
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Objectives: It is estimated that the prevalence of moderate-to-severe SA (apnoea-
hypopnoea index > 15/h) is 10%. Patients with T2DM have a particularly high inci-
dence of SA. T2DM and SA influence the development and progression of each 
other. This study investigated the effects of PAP therapy in SA patients with T2DM 
on all-cause mortality and cost of illness (COI) in Germany from a statutory health 
insurance (SHI) perspective. MethOds: A total of > 4 million individuals covered by 
the SHI database were analysed (≈5% of the German SHI population). PAP therapy 
was initiated in 4,068 patients with SA (PAP group). Propensity score matching 
was used to define a control group (CG) of 4,068 SA patients matched for age, sex, 
risk factors/aetiology, region and medication who received usual care (no PAP). Of 
these, 1,280 patients in the PAP group and 1,186 patients in the CG had comorbid 
T2DM. This subgroup of patients was followed for 3 years after initiation of PAP 
therapy. Results: Total COI was higher in the PAP group versus CG in year 1 (€ 8,105 
vs € 7,037, p< 0.0001). After 2 years’ follow-up, COI in the PAP group decreased but 
remained higher versus CG (€ 6,842 vs € 6,625, p< 0.001). After 3 years, PAP group COI 
associated with manually coded meters (model 1 and model 2) and autocoded meters 
(model 3). Cost data was based on median prices for medicines, devices, medical 
services in National health care system in the Russian Federation. Results: Annual 
direct costs per patient in the group of manually coded glucose meters were 1533 euro 
(model 1) and 1574 euro (model 2), and in the group of autocoded meters were 1557 
euro (model 3). Annual total costs per patient in the group of manually coded glucose 
meters were 2992 euro (model 1) and 2921 euro (model 2), and in the group of auto-
coded meters were 3034 euro (model 3). Cost-effectiveness ratio for autocoded meters 
was 1875 euro (model 3) and for manually coded meters was 1954 euro (model 1) and 
1982 euro (model 2) per 1 LYG, respectively (discounted at 3%). Budget impact analysis 
showed that use of autocoded meters (model 3) instead of manually coded (model 
1 and model 2) leads to the annually cost savings of 33 euro and 53 euro per patient, 
respectively (discounted at 3%). cOnclusiOns: Obtained results approve the use of 
autocoded blood glucose meters instead of manually coded blood glucose meters to 
administrate blood glucose level as part of intensive glucose-lowering therapy from 
a pharmacoeconomic point of view.
PDB36
HEaltH Economic imPact of Bariatric SurgEry rEviStED: StructurED 
rEviEW of litEraturE anD HEaltH tEcHnology aSSESSmEntS
Chawla A.S.1, Tao C.2, Faulkner E.C.3, Hsiao C.W.4, Patkar A.D.5, Romney M.6
1Quintiles Consulting, Durham, NC, USA, 2Quintiles Consulting, Cambridge, MA, USA, 3Institute 
for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of 
North Carolina, Chapel Hill, NC, USA, 4Johnson and Johnson Medical Companies, Markham, ON, 
Canada, 5Ethicon, Inc, Somerville, NJ, USA, 6Jefferson School of Population Health, Philadelphia, 
PA, USA
Objectives: The costs of obesity are staggering, accounting for 2-6% of global 
health care costs. The health economic benefits of bariatric surgery while notable, 
are multi-faceted, resulting in heterogeneous reporting in the literature. To that 
end, this study seeks to 1) highlight available evidence of the health economic 
impact of bariatric surgery, and to 2) identify key gaps in current evidence that 
may influence uptake by health care systems. MethOds: Evidence of the health 
economic impact was collated from 107 scientific articles, of which 19 were sys-
tematic reviews, published between 2010-March 2014 and archived in MEDLINE and 
PubMed. Additionally, HTAWatch identified 10 HTAs, largely from North America 
and the EU that evaluated economic benefits. Results: In all countries where 
evaluated, bariatric surgery was cost-effective compared to non-surgical therapy. 
The surgery was likely more cost-effective with higher patient BMI and with comor-
bidities, especially for BMI> 40kg/m2, although estimates varied. Furthermore, 
resolution of underlying comorbidities resulted in reduced utilization of health 
care services, pharmaceutical utilization, and improved work productivity, among 
others, resulting in cost saving of 60-70% relative to standard care over a 3-year 
period. Importantly, time to break even was typically in the 4-7 years range, and 
was shorter for patients with Type 2 Diabetes Mellitus (T2DM) and with BMI> 40kg/
m2, typically in the 1.25-5 year range. Three key evidence gaps were identified: few 
studies computed long-term cost-effectiveness; no head-to-head trials have directly 
compared different surgical procedures; and heterogeneity across populations and 
health system impede meta-analyses of patient outcomes such as QoL and long-
term health benefits. cOnclusiOns: Although heterogeneous, reports of health 
economic benefits of bariatric surgery indicate an overall positive trend, largely 
via reduction of health resource utilization. To firmly establish its impact, future 
studies need to conduct head-to-head comparisons, determine optimal patient 
populations, and employ standard clinical endpoints to demonstrate real world, 
long-term benefits.
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Objectives: Type 2-diabetes and excess weight incur large costs to health care 
systems, but the association between weight progression in diabetes and health 
care costs is unknown. We investigated those relations using real world data 
in a sample of newly diagnosed diabetes patients in Sweden by using repeated 
body mass index (BMI) measurement and health care resource utilization 
data MethOds: Patients with a BMI (kg/m2) measure at diagnosis and subsequent 
BMI measures at 12,24,36,48, and 60 months were identified from a previously 
conducted register study. Individuals were classified into three groups based on 
their BMI change over 5 years: increase (> 1 BMI unit increase), decrease (> 1 BMI 
unit decrease), and stable (≤ 1 BMI unit change). Each group was stratified by BMI 
at diagnosis (BMI 18-25; 25-30; ≥ 30). Health care costs for each group were esti-
mated by applying Swedish unit costs to the health care resource data extracted 
from electronic patient journals and a national patient register. Results: The 
study included 903 T2D patients (women, 43%; mean age, 62; mean HbA1c, 6.78%; 
mean BMI, 30.9). The BMI increased, decreased, or remained stable in 178 (20%), 
387 (43%), and 338 (37%) patients, respectively. Among patients with baseline BMI 
18-25 (n= 104), the five year cumulative health care costs were € 13,695, € 9,059, 
€ 8,936, in the increase, decrease, and stable group, respectively. Corresponding 
figures were € 11,470, € 7,950, € 8,683 for patients with baseline BMI 25-30 (n= 321), 
€ 14,387, € 9,465, and € 9,302 for patients with BMI ≥ 30 (n= 478). cOnclusiOns: In 
newly diagnosed diabetes, an increase in BMI lead to increased health care costs, 
irrespective of baseline BMI. Linking registry data on repeated BMI measurements 
and health care utilization is a valuable approach to investigate the association 
between weight changes and costs. Costs of interventions that maintain weight 
in patients with diabetes should be considered in the context of costs associated 
with weight gain.
